Kane Biotech Announces Distribution Agreement with Razan Medical Trading for revyve™ Antimicrobial Wound Gel
August 22, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has signed a three year distribution...
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Study Evaluating the Value of Vendaje® Compared to the Standard of Care for Non-Healing Diabetic Foot Ulcers
August 21, 2024 07:00 ET
|
Biostem Technologies
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Study Evaluating the Value of Vendaje®
Crescent Innovations reports strong interest in asset sale
August 13, 2024 08:30 ET
|
Crescent Innovations Inc.
Crescent Innovations Inc. reports that activity surrounding sale of its joint, bone and skin repair technology remains strong even at this late date.
ViaDerma Announces Shipment of 500,000 Units of its Flagship Product to Nigeria
August 13, 2024 08:00 ET
|
ViaDerma, Inc.
LOS ANGELES, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC: VDRM), a leader in innovative wound care solutions, is excited to announce that a shipment of 500,000 units of its flagship...
BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million
August 12, 2024 16:14 ET
|
Biostem Technologies
BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million
BioStem Technologies to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024
August 05, 2024 08:00 ET
|
Biostem Technologies
BioStem Technologies to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024
Kane Biotech Receives FDA Approval to Increase Dosage Allowance of its revyve™ Antimicrobial Wound Gel
July 23, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, July 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that the US Food and Drug Administration (FDA)...
BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers
July 10, 2024 07:15 ET
|
Biostem Technologies
BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers
Kane Biotech Makes First Commercial Sale of revyve™ Antimicrobial Wound Gel to ProgenaCare Global
June 27, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, June 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has made its first commercial-scale sale of...
BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study
June 26, 2024 08:30 ET
|
Biostem Technologies
BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study